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a b s t r a c t
Objective: The objective was to define the term evidence based nutrition on the basis of expert
discussions and scientific evidence.
Methods and procedures: Themethod used is the establishedHohenheim Consensus Conference. The
term “Hohenheim Consensus Conference” defines conferences dealing with nutrition-related topics.
The major aim of the conference is to review the state of the art of a given topic with experts from
different areas (basic science, clinicians, epidemiologists, etc.). Based on eight to 12 questions, the
experts discuss short answers and try to come to a consensus. A scientifically based text is formulated
that justifies the consensus answer. To discuss the requirements for the scientific substantiation of
claims, the 26th Hohenheim Consensus Conference gathered the views of many academic experts in
the field of nutritional research and asked these experts to address the various aspects of a claims
substantiation process and the possibilities and limitations of the different approaches.
Results: The experts spent a day presenting and discussing their views and arrived at several
consensus statements that can serve as guidance for bodies performing claims assessments in the
framework of regulatory systems.
Conclusion: The 26th Hohenheim Consensus Conference addresses some general aspects and
describes the current scientific status from the point of view of six case studies to illustrate specific
areas of scientific interest: carotenoids and vitaminA in relation to age-relatedmaculardegeneration,
the quality of carbohydrates (as expressedby the glycemic index) in relation tohealth andwell-being,
probiotics in relation to intestinal and immune functions, micronutrient intake and maintenance of
normal body functions, and food components with antioxidative properties and health benefits.
 2011 Published by Elsevier Inc.
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Introduction
An important objective of global regulatory legislation is to
ensure that health claims on foods and food constituents can be
properly justified and scientifically substantiated. Consumers
should be able to make choices based on clear and accurate
information and have confidence in the scientific and regulatory
processes used to support health claims. Any framework must
not only protect consumers from false andmisleading claims but
also satisfy the needs of industry to promote and innovate, to
stimulate multidisciplinary research, and to reinvigorate efforts
to process and preserve raw materials from agriculture, horti-
culture, fisheries, and aquaculture into a diverse range of foods
and food supplements.
Global regulatory frameworks currently reflect the role of
food and food constituents inmaintaining and promoting human
health and in decreasing the risk of disease. The purpose of this
consensus conference was to consider recent developments and
initiatives on the scientific substantiation of health claims and to
pay particular attention to the following items.
 The assessment of the totality of the available data and the
need for the development of a scientific framework for
weighing the strength, consistency, biological plausibility,
and coherence of the evidence.
 A critical examination of the application of the model for
evidence-based medicine in nutrition science; evidence-
based medicine is designed to evaluate the effects of drugs
and not the unique properties, complex effects, and inter-
actions of nutrients and bioactive substances.
 The need to address and define evidence-based nutrition, to
embrace state-of-the-art nutrition science, and to stimulate
future academic research.
 The identification and validation of relevant biomarkers that
can predict potential benefits relating to maintenance or
improvement of a function and those associated with
decreased risk of disease.
 The determination of the strength of recommendations to
reflect the available evidence and consensus among experts
in a particular field to communicate truthful nutritional and
health messages to the public.
The final decision onwhether or not a claim should be allowed
rests with the regulators and policymanagers, taking into account
the scientific assessments of the strength and coherence of the
evidence and other societal and health policy considerations
including the broader purposes of food labeling and claims to help
and improve the public understanding of nutrition and to support
strategies for public health promotion and improvement.
To discuss the requirements for the scientific substantiation of
claims, the 26th Hohenheim Consensus Conference gathered the
views of many academic experts in the field of nutritional research
and asked these experts to address the various aspects of a claims
substantiation process and the possibilities and limitations of the
different approaches. The experts spent a day presenting and dis-
cussing their views and arrived at some consensus statements that
can serve as guidance for bodies performing claims assessments in
the framework of regulatory systems. This report addresses several
general aspects and describes the current scientific status from the
point of view of five case studies to illustrate specific relevant
perspectives:
 Carotenoids and Vitamin A in relation to age-related macular
degeneration (AMD).
 The quality of carbohydrates (as expressed by the glycemic
index [GI]) in relation to health and well-being.
 Probiotics in relation to intestinal and immune functions.
 Micronutrient intake andmaintenance of normal body functions.
 Food components with antioxidative properties and health
benefits.
I. Assessing the totality of the available evidence for
diet–health relations
This section discusses methodologies for assessing the validity of
diet–health relations, with a particular focus on how to consider the
totality of the available data, weigh the evidence, and address the
strength, consistency, and biological plausibility of a particular diet
and health relation. It also deals with requirements and processes to
develop research methodologies to demonstrate beneficial effects in
a healthy population.
Consensus statements
There is a need for a scientific framework for the assessment of
health claims describing the methodology on how to consider the
totality of the evidence and weighing the strength, consistency, and
biological plausibility of the available evidence.
The Process for the Assessment of Scientific Support for Claims on
Foods (PASSCLAIM) described criteria and standards by which the
quality and relevance of the scientific evidence should be presented
for evaluation and thus the extent to which claims based on them
can be said to be scientifically valid. PASSCLAIM provided a scientific
framework to facilitate the assessment of scientific support for
claims on foods, but the project did not specifically address how the
totality of the evidence should be weighed.
A key question is how best existing and new methods can be
used to determine transparently the weight of evidence in such
a way that the totality of the available data can be evaluated. There
aremanymethods for weighing the evidence (Appendix) that can be
used to show the extent to which a cause-and-effect relation is
determined, taking into account the nature, quantity, and quality of
the different sources of evidence. The scientific framework and
criteria for substantiation of claims should be applied intelligently
and sensitively to existing and potential claims on a case-by-case
basis with respect to gaps in existing knowledge and to the devel-
opment of new knowledge.
There is a need to define “generally accepted scientific evidence.”
There is a need for broad more consensus-based agreements on the
scientific substantiation of claims, i.e., for bringing together the
experts in the field and let them reach agreement on the totality of
the available data and weight of the evidence based on their
accepted opinion that is generally held to be correct.
There is a need to translate broad fields of health (e.g., complex
physiologic functions such as immune and gastrointestinal func-
tions) into a framework of (bio-)markers and other evidence that
would be required to sufficiently substantiate the effect for the
maintenance of the function.
The terminologies of “grading of evidence,” which is widely used
for the development of nutritional recommendations and which
may result in differentiation of claims wordings dependent on the
strength of the supporting evidence, constitute a valuable concept
that needs to be further explored and applied.
1. What approaches exist and are used to consider the totality of
the available data, weigh the evidence, and address the strength,
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consistency, and biological plausibility of the relation between diet
and health?
Background
The public’s increasing awareness that nutrition and dietary
components contribute significantly to personal well-being and
health, and to public health overall, opened up opportunities and
a need to make claims about the benefits of particular foods or of
foods components. In consequence, there was an increase in
claims about the relations between the consumption of partic-
ular food categories, foods, or food constituents and a specific
benefit to health. These claims were usually designed to promote
a particular product in the face of market competition. The
quality of the evidence underpinning such claims was variable,
although some claims derived from generally accepted knowl-
edge, which may not be as sound as nutritional science accepts.
Others were based on selective and non-robust extrapolations
from observational studies, notions that larger intakes of
components must endow correspondingly more benefit, folk-
loric associations, and perhaps more from aspiration rather than
empiricism [1,2]. Thus a range of products appeared spanning
a spectrum of traditional food products that had been fortified or
enriched with specific components to completely novel prod-
ucts. This was the start of the era of what became called “func-
tional foods.”
These developments coincided with national and interna-
tional reviews of reference intakes for nutrients. These reviews
demonstrated the limitations of the information from which
reference intakes were induced, and they highlighted a need to
strengthen the science base. There emerged a movement,
evidence-based nutrition, akin, but not necessarily analogous to
evidence-based pharmacology and evidence-based medicine.
Although evidence-based nutrition and evidence-based medi-
cine are not fully analogous, both benefit from a core objectivity
and criticality, and it was appreciated that more hypothesis-
based approaches were needed in nutritional science. This
particularly applied within the global food economy, which was
becoming imbalanced by the use of unregulated and unsub-
stantiated claims [2]. In consequence, the European Union fun-
ded an International Life Sciences Institute (ILSI) that hosted
a Concerted Action on Functional Science in Europe (FUFOSE),
the purpose of which was to characterize the evidence against
which a functional effect could be judged [1]. Thus FUFOSE met
the needs of those developing new products with a focus on very
specific health benefits and strong claims and of those who
wished to see more rigorous evidential approaches adopted
within nutritional science (see below).
Causality and claims
Causality and a claim are two different things. Causality
clearly is an integral component of justifying a claim, but
causality and claims need to be differentiated from each other.
FUFOSE and PASSCLAIM deal with the evidence for causality, i.e.,
the demonstration of the extent to which a cause-and-effect
relation is established. The presented evidence of causality is
subjected to a scientific appraisal by an independent and
competent agency. This independent assessment should then, as
was stated in the INTRODUCTION, be reviewed in a broader context
by policy makers and regulators in the regulatory authority that
allows claims.
Thus the establishment of a claim comprises two elements.
The first is the assessment of the evidence to support the extent
to which a causal relation has been demonstrated between
a food or food constituent at a specific exposure and a health
outcome of interest, and the second is the use of this information
in the context of other appropriate considerations to determine
whether or not a claim might be justified and what the precise
character of that claim might be, i.e., whether it should be
qualified in any way.
Thus the assessment of the extent of causality involves
a consideration of all the available information against criteria
that depend on the causal relation being justified. Although it
may not be essential to know the underlying mechanism for this
relation, having one and a related hypothesis would appreciably
help the selection, quality assurance, validation, compilation, and
presentation of the evidence.
Demonstrating causality: quality of the evidence
The essence of good evidence is that it uses objective and
valid information suitable for the intended purpose. Enough
evidence is the amount that establishes the clearest assessment
of the probability of an association between a specific exposure
or event and a specific outcome. When assessing the validity of
a claim, the reviewing bodies should have access to and consider
on their scientific merit all relevant data including those studies
that may provide conflicting evidence.
The quality of the markers and outcomes used in substanti-
ating a causal relation is crucial and their quality characteristics
are common to all good scientific experimental practice. FUFOSE
explained these in the context of nutritional science and
provided a strategy for their use in nutritional interventional and
observational studies, and it assumed that it should be possible
to envisage and possibly show the chain of events from eating
the component of interest to the final outcome [1]. Integral to
this was the use of markers for 1) consumption or external
exposure, 2) internal exposure or body burden, 3) intermediate
metabolism and the production of active metabolites with, if
possible, a quantitative assessment thereof, thesemarkers would
represent target function and biological responses, 4) interme-
diate endpoints, and, if possible, 5) an endpoint directly identi-
fied with a decreased risk of disease (Fig. 1).
Ideally evidence, based on a series of markers, could be pre-
sented to justify a causal chain of events from early exposure to
the desired outcome measurement. However, as Figure 1 illus-
trates, each event could lead to other events that are not related
to the outcome of interest. Furthermore, there may be limited
evidence of links between the various “steps,” and each hypo-
thetical step may have many other components, so a simplified
figure was developed to represent and summarize the key
outcome of FUFOSE in terms of the types of markers [1] (Fig. 2).
Fig. 1. The chain of markers: consumption to outcome. Principle of a pathophysi-
ologic pathway.
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In addition, FUFOSE emphasized the principle that markers
representing an event directly (i.e., causally) involved in the
beneficial or potentially pathogenic process could be regarded as
factors, whereas those representing correlated but not identifi-
ably causative events should be considered indicators.
The more temporally or mechanistically remote a marker is
from the target endpoint, the less specific and more attenuated
and subject to confounding variables it becomes. Conversely, the
closer the marker is to the endpoint in question, the more likely
it is to be specific and quantitatively related to the outcome and
as such to be a factor rather than an indicator. Clearly the
elucidation of the mechanisms leading to health outcomes
would refine the identification of markers and their use in
experimental and observational studies.
The FUFOSE made the following additional points about
markers [1]. Overall, markers should be feasible, valid, repro-
ducible, sensitive, and specific. These qualities are applicable to
markers whatever their nature (see below). In an experimental
study markers should represent relatively immediate outcomes,
which can be used to assess interventions in a reasonable time
scale; they could, therefore, wherever possible, replace later and
more remote outcomes as have been used in some epidemiologic
studies. They need to be subjected to the accepted standard
procedures for quality assurance. They must also be validated in
the context in which they are being used, i.e., to measure dietary
intake, internal burden, or intermediate or final outcomes.
Markers are also more credible if they have undergone studies to
establish their sensitivity (i.e., the frequency of a negative test
when the process is present) and their specificity (i.e., the
frequency of a positive test when the process is absent), and they
must be shown to be reproducible in different centers.
Understandably markers would need to be measured or
derived from easily accessible material or obtainable using
methodologies that must be ethical and minimally invasive.
The FUFOSE consensus eschewed the term biomarker, which
has biochemical connotations. It preferred markers because this
acknowledged the broad range of available and applicable
markers. Thus, apart from biochemical markers, study outcomes
can quite feasibly be derived from, among others, behavioral or
psychometric outcomes, physiologic performance, adaptive
phenomena, and metabolic clearance studies; indeed, dynamic
responses might be as useful as, or more useful than, static
measurements. In fact, any marker that can be quality assured
and validated should be appropriate for establishing causality.
Often, it is likely that a “battery” of markers might be needed
to address the perspectives of evidence appraisal outlined below
for multiple and variable sources of data [3]. In fact, given the
quality of data available for health claims, these considerations
about markers should inform “new human intervention studies
using appropriate markers to generate readily interpretable,
valid and reliable data” [1].
One can accept that the FUFOSE strategy of using markers
from a sequential path of events leading to the hypothesized
benefit or decreased risk is an ideal. Nonetheless, it epitomized
the need for a strategic approach to the acquisition and analysis
of data, and it emphasized the need for and the validation and
quality assurance of data and its overall structured integration
Thus these principles would be relevant to the design of studies
to obtain new data and to the evaluation of existing data. FUFOSE
provides away to assess the quality and relevance of the markers
reported in studies and to evaluate the individual reports and
sources of information before they are included in a pool of total
evidence for collective evaluation and presentation. Interpreta-
tion and categorization of information according to the FUFOSE
strategy may also enable that information to demonstrate its
compatibility with Hill’s principles (see below).
All available information needs to describe all the identifiable
uncertainties and variabilities affecting its interpretation (e.g.,
Fig. 3). Clearly these factors influence confidence in the subse-
quent assessment of causality and, in the context of regulatory
affairs, might be foreseen to influence the qualification of a claim
and any assessment of safe upper limits of exposure to the food
or food component.
Although this section has been written with human studies
and applications in mind, it has not considered which data
could be derived from animal or other model systems and
which would be needed for human studies. The FUFOSE and
the subsequent concerted action, PASSCLAIM, considered this
and appreciated that markers, mechanisms, and plausibility
could be explored in systems in vitro and in vivo models and
that key data would be generated by appropriate human
studies [1].
Fig. 2. Concerted Action on Functional Science in Europe: from scientific evidence based on markers for functional foods to types of claims relevant to them [1].
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Demonstrating causality: types of evidence
In Europe, a subsequent concerted action, the PASSCLAIM,
also hosted by ILSI Europe, produced a generic tool for assessing
the scientific support for health claims of foods and established
criteria for markers that could be used to explore the links
between diet and health. The latter PASSCLAIM criteria endorsed
the FUFOSE proposals on markers and the strategy for their use.
It also provided guidance on the overall portfolio of evidence
submitted to support a health claim [4]. Essentially, PASSCLAIM
stated that the portfolio should provide information on the
characteristics of the food component or food under study and
that the portfolio should contain evidence from human studies,
preferably prospective intervention studies, in which 1) the
study groups are representative of the target group and appro-
priately “controlled”; 2) there is an adequate duration of expo-
sure and follow-through demonstrate the intended effect; 3) the
study group’s background and exposure and other relevant
aspects of lifestyle are well characterized; 4) the amount of food
or food component eaten is consistent with its intended pattern
of use and the influence of the food and dietary matrix is known;
5) the participants’ compliance is monitored; and 6) the statis-
tical power is appropriate to test the hypothesized causality. The
PASSCLAIM criteria re-emphasized the quality criteria of the
markers used and the ideal need for dose-related biologically
appropriate changes in their values.
The PASSCLAIM emphasized that claims on foods should be
scientifically substantiated by taking into account the totality of
the available data and by weighing the evidence. It did not
provide specific guidelines as to how the data should be
weighed. Its advice constituted a guidance template to inform
the evaluative and regulatory processes and to enable the
assessment of the appropriateness of the received data for
assessment. The evidence supporting the extent to which
a causal relation can be inferred comprises five categories [5].
These are 1) experiments that probably can provide the strongest
idea of mechanisms with an immediacy between exposure and
outcome; 2) randomized controlled trials (RCTs); 3) regression
continuity designs; 4) natural experiments (random non-
manipulative biomedical occurrences in populations that can
be quantitatively and systematically analyzed); and 5) non-
experimental studies including cohort studies, case–control
studies, and ecological designs. All of these, with or without
corroborative information from animal studies can be used to
substantiate the extent to which causality can be demonstrated
[5]. PASSCLAIM deliberately did not rank these types of evidence,
in part because it was appreciated that each portfolio of evidence
would need to be considered in its own right and that this
process would probably involve different approaches to the
interpretation of the evidence and the uncertainties therein.
Note, however, the importance given in the prioritization to
studies that indicate mechanistic associations.
Thus PASSCLAIM set what could be regarded as a gold stan-
dard for the portfolio of evidence, but by not giving precedence
to any particular form of information. It left opportunities for an
informed and intelligent compositing and appraisal of the data
free from any distortions that might arise from giving greater
weight to some lesser-value information because it came from
a more highly ranked type of study. Even so, experience suggests
that current assessments depend very much on evidence from
RCTs. This was not PASSCLAIM’s intention. Unfortunately, PAS-
SCLAIM made no comment on how the overall totality of the
evidence should be weighed and interpreted. The possibilities
and limitations of the use of RCTs in the assessment of the
scientific evidence for diet–health relations are further discussed
in section III.
Demonstrating causality: totality of the evidence
Philosophically, nothing can be absolutely proved, but
a qualified and informed inference about the extent of causality
may be induced from appropriately constructed and collated
evidence. For individual studies and for quantitative data,
probability values infer a degree of causality. However, associa-
tion does not necessarily establish causality. Sir Austin Bradford
Hill noted that tests of significance (probability) inform on the
size of effects, but that as such they do not necessarily prove
causality [3]. He proposed nine viewpoints fromwhich evidence
of associations should be regarded and explored before deciding
that any association reflects causality.
1. Strength of the association: A close association is more likely
to indicate a causal relation but a slight association does not
exclude this possibility.
Fig. 3. Modifiers of effect and confounders of the evidence base and markers to explore causality (developed from the Concerted Action on Functional Science in Europe
schema [1]).
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2. Consistency: Consistent and reproducible associations
particular from different centers increase the likelihood of
a causative effect.
3. Specificity: Causative relations are more probable if there is
strong association between a specific agent and a particular
outcome.
4. Temporality: The outcome of interest must occur after the
specific exposure.
5. Biological gradient: There needs to be a clear dose–response
relation between consumption (external exposure) and/or
body burden (internal exposure) to the food component of
interest and the outcome. The relation may be direct or
inverse. It should be remembered that this relation is subject
to uncertainties arising from, among others, absorptive
efficiency, bioavailability, homeostasis, and metabolic
adaptation.
6. Plausibility: It would be helpful if any observed association is
biologically plausible.
7. Coherence: Interpreting data as evidence of causation needs
to be considered in the context of other epidemiologic and
laboratory findings and knowledge. If it fits, this increases
the likelihood of an effect. However, lack of a fit and absence
of other information does not negate causation.
8. Experiment: Hill’s viewpoints addressed observational data,
often from retrospective studies and non-interventional
data; thus the availability of well-designed experimental
studies in humans and animal models would improve the
coherence and plausibility within a portfolio of data.
9. Analogy: The effect of similar factors in other foods and the
diet may be considered as part of the overall scenario of data.
Hill wrote that “none of my nine viewpoints can bring
indisputable evidence for the cause and effect hypothesis and
none can be required as a sine qua non. What they can do, with
greater or less strength is to help us make up our minds on the
fundamental questiondis there any other way of explaining the
set of facts before us, is there any other answer equally, or more,
likely than cause and effect?” [3]. The nine viewpoints are not
a checklist; indeed, one of the reasons for setting the viewpoints
was to provide an approach to the interpretation of portfolios of
data and to provide a way to compensate for data gaps.
It can be easily appreciated that Hill’s viewpoints could also
be applied to individual studies and to portfolios of evidence.
Thus these criteria, as they became known, provided an addi-
tional tool for assessing individual studies. They were developed
before the use of RCTs became extensively used. Thus, Hill’s
criteria, which had been developed to assess epidemiologic or
observational data, became used to inform RCT designs and to
grade types of evidence.
The development of RCTs was given appreciable impetus by
their potential ability to address most of Hill’s criteria and
simultaneously to compensate for confounders and uncer-
tainties. However, the value of RCTs is often over-rated and they
have limitations caused by their focused character, their
dependence on the design study to deal with uncertainties and
confounders, and their lack of generalizability to other sectors of
the population that were not represented by the study group.
Furthermore, good RCTs are expensive and difficult to apply to
long-term outcomes such as those representing health and well-
being and decreasing disease risk. They are also difficult to
manage if they involve a sustained intervention and follow-up. In
short, RCTs are a difficult tool for nutritional studies, unless, of
course, the food component of interest has much in common
with a pharmaceutical compound [5,6].
Irrespective of the types of evidence, if any portfolio has
good quality evidence based on appropriate markers used in
a mechanistic strategy derived from good quality studies (such
as has been advocated in the FUFOSE and in PASSCLAIM), Hill’s
criteria lend themselves to the creation and analysis of a well-
structured argument for causality. Thus if the data presented
in a portfolio essentially meet the elements of FUFOSE and
PASSCLAIM, then the completeness of the dataset can be gauged
by the degree with which the information overall addresses the
elements of Hill’s criteria and maintains the integrity of the
overall case in which the “totality of the evidence” is brought
together to produce a coherent exposition of the case for
establishing the extent of causality. The quality of the evidence
is pivotal to this.
The flexibility of Hill’s criteria to different types of evidence is
becoming better appreciated. Importantly, proposed revisions of
Hill’s criteria are showing how the initial guidelines of experi-
mental strength and temporality can be regarded as direct
evidence, whereas those of biological gradient and biological
plausibility are seen as mechanistic evidence; the criteria on
coherence, consistency, and analogy can be seen to represent
coherence, repeatability, and similarity as a group of parallel
evidence [7]. Using this configuration, it can be shown how
“evidence-based mechanistic reasoning” can be applied to
demonstrating causality within the context of using Hill’s criteria
to assess the totality of the data [8]. These studies illustrate how
awell-structured mechanistic pathway or process can be used to
substantiate the extent to which causality can be demonstrated
in the absence of RCTs or in the presence of weak RCTs. In the
latter case, this adds weight to the criticisms of overdependence
on RCTs in nutritional research and the need to use alternative
forms of evidence of causality in nutrition [6]. The concept of
evidence-based mechanistic reasoning is also consistent with
the strategic use of markers for individual studies and the linking
of independent studies proposed by FUFOSE [1].
Another proposed benefit of using Hill’s criteria was that
these provided a framework within which allowance could be
made for incomplete datasets and missing information. Statis-
tical devices can be used to enable imputation approaches for
missing data points, for the aggregation of incomplete datasets
to enable “broken RCT analysis,” and for the statistical random-
ization of observational data [9]. Hill (1965) however warned
against over precise use of analyses in the face of large systematic
variation, and there may be inherent dangers in such manipu-
lation of the data. Conversely, there is an increasing attention to
the philosophy of using qualitative studies in exploring causality
in the social sciences, education, and some aspects of health care
[3,10,11].
Demonstrating causality: grading of the evidence
One of the problems associated with the assessment of
scientific data underlying the relation between intake of a food
or food component and an effect on health is how to deal with
emerging science. By its very nature, emerging science is indic-
ative of a health effect but needs further corroboration before it
can be generally accepted as conclusive. Such corroboration can
come from further controlled trials but also from other sources of
evidence pointing toward the plausibility of the observed effect
(e.g., experimental and animal studies supporting a plausible
biological mechanism, observational evidence confirming the
observed effect, etc.).
The World Health Organization (WHO) and the World Cancer
Research Fund (WCRF) have applied a system of “grading” of
the evidence as a scientific methodology to assess the amount
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of evidence available and the strength and consistency of that
evidence to support the plausibility of the observed effects [12,
13]. This system uses four grades of evidence: convincing,
probable, possible, and insufficient. It has proved very helpful for
public health institutions in the development of science-based
public health recommendations.
Furthermore, if applied in the framework of claims assess-
ment, it would enable regulators to take decisions onwhether to
accept an observed effect by balancing the strength of the
claimed effect against the strength of the supportive evidence.
Furthermore, it is crucial to support scientific research and
product innovation to find an approach where the term generally
accepted scientific data includes not only generic or well-
established associations between a food or a food component
and a health benefit but takes also into account the overall
concept of the grades of evidence and the balance of probabilities
that an association between a food or a food component and
a health benefit will be refined (not reversed) by subsequent
scientific research (Fig. 4).
Similar systems have been proposed (Appendix). In
December 2004, the Netherlands Ministry of Health initiated
discussions on the establishment of an inventory of substan-
tiated health claims to fulfill the obligations of Article 13 of
the European Union (EU) claims legislation then under
development [14]. The basis of their proposed framework was
a judgment and classification of the foods and food compo-
nents and their health relations based on the strength and
consistency of the scientific evidence in such a way as to
underpin the definition of generally accepted scientific data.
The approach developed the PASSCLAIM concept of
a continuum of emerging and consensus science and used the
WHO/WCRF terminology to create five categories based on
the grade of evidence:
Categories 1 and 2: insufficient substantiation; more data
needed.
Category 3: probable/likely (possible); positive outweighs the
negative evidence; balance of probabilities justifies the diet–
health relation.
Categories 4 and 5: convincing; including evidence based on
meta-analysis, peer-reviewed publications, text books,
monographs, judgments by government-related organiza-
tions, scientific groups, or expert organizations (e.g., WHO,
European Food Safety Authority, UK Scientific Advisory
Committee on Nutrition).
This would enable assessors to identify generally accepted
relations between foods and food components and health. It
stresses the need to develop an acceptable procedure that takes
into account the fact that scientific knowledge is constantly
evolving and being refined.
Also, the European Medicines Agency proposed a system of
grading for determining the requirements for scientific data
underlying the various types of medicinal products [15].
Thus, the scientific grading of the evidence provides a way of
expressing an assessment of the totality of the information
available and enables a transparent scientific and qualified
judgment relating to the strength, consistency, and biological
plausibility of the relation between the intake of a food or food
component and its role and effects for health. The best resource
for assessing the totality of the evidence available in support of
the plausibility of the beneficial effects of a specific food
Fig. 4. Grading of the evidence. EFSA, European Food Safety Authority; FDA, Food and Drug Administration; AFSSA, Agence française de securite sanitaire des aliments; WHO,
World Health Organization; SACN, Scientific Advisory Committee on Nutrition; NAS, National Academy of Sciences; ESPHAGEN, European Society for Paediatric Gastroen-
terology; ESCOP, European Scientific Cooperative on Phytotherapy.
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component is obviously an assessment by the leading experts in
field. Such “consensus” meetings would be able to provide the
best clarity on the current status of the scientific research,
including its limitations and identify future research needs. It
would also provide regulators with a sound foundation onwhich
to base decisions for public health recommendations and the
acceptance of health claims.
Assessing a claim
Assessment of the overall case for a claim is a risk-
management process that should be taken by competent regu-
latory authorities. This agency would be provided with an
assessment of the strength, consistency, and biological plausi-
bility of the evidence for a health claim. Ideally this assessment
would provide an explicit consideration of the weaknesses and
strengths of the portfolio of evidence of causality and an account
of the uncertainties and variabilities of the data as would be
expected with a risk or scientific assessment.
Because the regulators will also need to consider the potential
benefits and harms that might arise from their decision, the
probability of these events would also need to be considered. It
has been argued that assessments of degree of causality might be
influenced by an awareness of the potential harm of not attrib-
uting or attributing causality. Thus, risk–benefit analysis might
need to be a separate exercise from that of assessing the extent to
which causality can be demonstrated [16].
The PASSCLAIM did not consider the qualification of claims
should they be allowed. Various frameworks have been
proposed, but the criteria for scientifically grading the strength
of the evidence for causality have not been well defined. The
grading of evidence in support of causality need not be the same
as the grading of the contingent claim.
The competent authority would be expected to have other
issues in mind when it decides whether to allow a claim. Such
issues would include public health protection, public health
improvement, enabling commercial freedom, and equitability in
the market.
2. What is the process and what are the requirements to develop
research methodologies that are able to demonstrate beneficial
health effects on bodily functions in normal healthy populations?
Background
The primary goal of nutrition is to maintain, or if possible to
improve, health. This is an essential difference from pharma-
ceuticals, which are generally developed to treat, cure, or prevent
disease. The term beneficial physiologic effect refers to the
demonstrable effect(s) of a food or food constituent for which
a health claim is made. Beneficial physiologic effects go beyond
traditionally accepted nutritional effects and their validity
should be substantiated for the general population or a pop-
ulation subgroup. This requirement to demonstrate a beneficial
physiologic effect(s) of a food or food constituent in the general
healthy population presents an enormous scientific challenge to
nutrition science. In fact, this task is more complicated than
assessing the efficacy of most pharmaceuticals, for which effects
on clinical or surrogate endpoints are often easier to establish.
The question on how to develop new research strategies will
be split into the following subquestions: How to define and
measure health? How healthy is the target population? How to
demonstrate beneficial physiologic effects in persons who are
healthy?
What is health?
According to the WHO definition, health can be defined as “a
state of complete physical, mental and social well-being and not
merely the absence of disease or infirmity” [17]. This definition
takes into account that health may still be improved even if there
are no obvious physical or mental conditions. However, it does
not provide directions on how to quantify improvements in
health, in particular not on a population scale. Therefore, it is
proposed to use a definition that is based on the principles of
homeostasis and at least one aspect of the dynamic of biological
evolution: “health is the ability to adapt to internal and external
stimuli” [18,19]. Homeostasis acts tomaintain balance among the
various biological processes that are interacting in an individual.
The dynamics of these processes can be studied by looking at
clusters of functional biomarkers, which in a healthy state are
kept within a certain range. When there is long-lasting imbal-
ance between the physical and mental robustness (adaptability)
of an organism and external and internal stimuli, the risk for
permanent harm (pathology) increases. The robustness of
homeostasis at a particular moment can be determined using
so-called challenge tests. It should be realized that health is
time-dependent. Although a person can be healthy at a particular
moment as shown by adaptability, there is a certain likelihood
that genetic makeup and environmental factorswill changed this
situation over time. This is called risk for disease. Currently,
European legislation interprets beneficial physiologic effects in
this case as to whether the food or constituent decreases the risk
factor for the development of a human disease (not the risk of
the disease itself). This interpretation can lead to complicated
situations, e.g., the true outcome of a disease such as a cardiac
event for coronary heart disease that is based on strong epide-
miologic evidence and quantification of relative risk but no
decreased risk factor from RCTs. These sorts of situations may
occur, for example, with diseases for which no clear risk factor
has been established or for which there is a lack of scientific
consensus on the predictive value of such a risk factor. As a result,
it might even happen that a food product that has shown to
effectively decrease the risk for a particular disease can still be
refused a health claim in the absence of an established and
decreased risk factor. Clearly, there is a need for a review of the
scientific implications of the absence of an established decreased
risk factor in making claims for decreasing disease risk.
With regard to risk factors, there are several ways by which
these may be modulated by diet or specific nutrients, e.g., at the
molecular level. However, there is notmuch knownyet about the
interpretation of such interactions, in particular in the longer
term. Therefore, it is recommended to adopt the establishment
and validation of risk factors as a future research priority. Expert
groups could be formed to reach greater consensus on the
acceptability of potential risk factors. More fundamental
research, e.g., in epigenetics, is needed on the interaction
between genetic risk factors and nutrients. This discussion also
identifies the option to abandon the “risk-factor” approach and
refocus on biomarkers of optimal health based on the homeo-
stasis concept. This is further discussed in section IV.
How healthy is the target population?
Inmany cases, the boundaries between health and disease are
not well defined. Increasing knowledge on how diseases develop
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and improved diagnostics have demonstrated that there is often
a continuum between a healthy state and disease. At any given
time, the general population consists of only a minor fraction
that is “perfectly healthy,” whereas the majority is somewhere
between an overt disease status and the “perfect-health” status.
This holds particularly true for chronic diseases. For example,
overweight (body mass index >25 kg/m2) and obesity (body
mass index >30 kg/m2) currently affect more than 50 % of the
adult population in the USA and Western Europe. Both condi-
tions are important risk factors for diabetes type 2 and cardio-
vascular disease and contribute to the development of secondary
complications. Persons who are overweight or obese often show
increased markers for inflammation, deviant serum lipid
profiles, increased liver enzyme values, and a slightly increased
blood pressure without being diagnosed as patients. Therefore,
to demonstrate beneficial physiologic effects, evidence in slightly
impaired individuals may represent an alternative approach [18].
Clusters of biomarkers that reflect essential processes such as
inflammation, oxidative stress, or metabolism can be used to
construct a theoretical multidimensional “health space” [20].
This approach helps to reveal biological processes that may be
functioning suboptimally and can be used to show more specific
beneficial effects of intervention.
How to demonstrate beneficial physiologic effects in persons who
are healthy?
Methods based on analysis of the robustness of physiologic
homeostasis in individuals are currently regarded as the most
promising approaches to measure health and beneficial physio-
logic effects of nutrition. Such approaches are generally
following a challenge principle. Challenge tests should cover one
or several relevant physiologic processes. Examples include
variations of oral glucose and lipid tolerance tests, organ function
tests, exercise, or even psychological stress challenges [21].
Although some of these tests, e.g., the glucose tolerance test, are
not new, the combination with new bioanalytical technologies
(microarray analysis and metabolomics) and calculation power
makes them particularly useful to test health-improving effects
of foods and food constituents. The designs of the tests should be
optimized to include analyzing the time course of physiologic
processes instead of single endpoints. In general, the interven-
tion will take place after a crossover design, using a placebo if
possible, with each participant being his/her own control.
Although this will require intensive sampling and measurement
schedules for each participant, this decreases the effect of
interindividual variation and allows smaller numbers of partic-
ipants per study. Challenge tests are promising for quantification
of phenotypic changes and health effects of nutrition based on
homoeostatic adaptability, but there remain certainly issues to
be resolved. These include the nature of the challenge, the force
of the stimulus, accepted designs, statistics, and validation.
Therefore, it is recommended to further develop and evaluate
these approaches as concerted activities. As was also recently
advised by the Proving the Efficacy of Foods and Food Constit-
uents for Health Claims (PROCLAIM) taskforce, this should
preferably be organized by international research consortia in
which industry and academic groups work together [18].
II. Case studies
In this section several case studieswere discussed to address under
what conditions the totality of the current scientific data and
supportive evidence from generally accepted sources and recognized
scientific institutions could find more suitable alternatives to RCTs.
These case studies address the following diet–health relations:
 Carotenoids and vitamin A in relation to AMD.
 The quality of carbohydrates (as expressed by the GI) in relation
to health and well-being.
 Probiotics in relation to intestinal and immune functions.
 Micronutrient intake and maintenance of normal body
functions.
 Food components with antioxidative properties and health
benefits.
 The nature of evidence supporting the impact of deficient,
adequate, and optimal intakes of micronutrients on physiologic
function.
The case studies were chosen as examples to address several
questions, including:
 How far is an evidence-based benefit a reliable endpoint?
 To what extent are the data and practical experience of health
care professionals capable of providing additional scientific
support?
 To what extent can data from clinical studies of disease states
be used as supportive evidence for health effects?
 How to assess the different effects of the various nutritional
components from the diet on systemic parameters, e.g., the
individual effects of the various types of fatty acids in the diet
on blood lipids, the individual effects of the various types of
carbohydrates and carbohydrate-containing foods on meta-
bolic and glycemic responses, and in particular the effects of
their mutual replacement in the diet.
 How to identify the value of changes in biological parameters of
complex physiologic systems (e.g., immune function, metabolic
responses) for the identification of beneficial effects.
Consensus statements
Practice and experience by health care professionals can be well
established but mostly are not documented and may therefore not
be part of the evidence currently required for a claims assessment.
However, these form part of the evidence acknowledged by the
experts in the field. If because of this situation claims are rejected,
consumers are denied the use of information on products, despite
their physicians or other health care workers advising them.
Although the review process of health claims has identified the
weaknesses of current nutritional research (and the peer-review
process), the acquired scientific knowledge available to date
cannot be ignored and should be a starting point for the assessment
of the totality of the available data and the strength, consistency,
and biological plausibility of the evidence and for the identification
of stronger research concepts.
There is a need to point out that the focus on the presence of
a decreased risk factor is a limiting factor and that foods and food
constituents can have an effect on the decrease of a disease risk,
although a risk factor cannot be identified. Nutritional risk factors
should also be acceptable.
There are specific areas that appear not to fit the legal frame-
work for the assessment of the claims, such as GI claims (as defined
by the claimed effect) and botanicals (based on traditional use).
Instead of letting these established health effects fall out of the
framework, the regulatory framework should recognize the nature
and source of this evidence base and be modified to fit them in.
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There is a need to translate the impact of nutrition on health and
wellness (e.g., cognitive performance, inflammatory processes,
cardiovascular disease risk, etc.) into a framework of biomarkers
and physiologic responses sufficient to quantify and substantiate
these relations for the maintenance of a beneficial bodily function.
1. Carotenoids and vitamin A in relation to AMD
As far back as the ancient Egyptians, it was appreciated that
night blindness could be treated with dietary interventions such
as the consumption of liver. Millennia later, it was demonstrated
through biochemical and animal studies that the liver is rich in
vitamin A whose metabolite, 11-cis-retinal, is critical for the
normal function of the rhodopsin photopigment in the human
retina. It also became clear that a non-essential nutrient
precursor of vitamin A, b-carotene, could substitute for vitamin A
in a manner that posed much less risk of toxic side effects. The
effects of b-carotene are so dramatic and clear-cut that it has
become widely accepted as a valid public health intervention
against eye diseases related to vitamin A deficiency in the
developing world without a large-scale RCT to support such
a claim.
Age-related macular degeneration is the leading cause of
blindness in people older than 50 y in the developed world [22].
The number of adults registered blind as a result of AMD in
industrialized countries continues to increase, primarily due to
increasing longevity [23]. Beyond its inevitable impact on the
individual, AMD poses a growing socioeconomic challenge to
modern society [24]. To determine the role of nutrients in the
maintenance of eye health is a challenging problem. AMD is
a slowly progressive complex disease influenced by genetics,
aging, andmultiple environmental factors including smoking and
light exposure [25]. Epidemiologic studies of the 1980s indicated
that diets rich in carotenoids could be a mitigating factor for the
risk of AMD. So,when the Age-Related EyeDisease Study (AREDS)
RCT was conceived, the best known and most widely available
carotenoid, b-carotene, was included with zinc, vitamin C, and
vitamin E. The positive AREDS results published in 2001 have had
a profound impact on clinical retina practice in the USA because
AREDS-type supplements are routinely prescribed to patients
with the intermediate to advanced stages of AMD, but the
recommendations were not without controversy [26].
There was no guidance as to whether AREDS supplements
would be helpful in patients with earlier stages of AMD or with
a strong family history. Because b-carotene, vitamin C, and
vitamin E were given together, it was not clear which nutrients
were actually driving the positive effects. Two other studies
published while AREDS was in progress found that high-dose b-
carotene supplementation significantly increases risk of lung
cancer in smokers [27,28]. Also, b-carotene itself is not found in
the retina, and its metabolism to vitamin A is tightly regulated.
As such, it became increasingly recognized that other caroten-
oids such as lutein and zeaxanthin, which are found in the
macula at high concentrations, might have been better choices
than b-carotene for intervention against AMD.
Indeed, after the inception of AREDS, it became clear from the
many epidemiologic and biochemical studies that lutein and
zeaxanthin, rather than b-carotene, are likely to be the protective
factors in carotenoid-rich fruits and vegetables [29]. Accordingly,
the AREDS2 study is testing lutein 10 mg and zeaxanthin 2 mg in
a randomized, placebo-controlled, double-blind clinical trial in
addition to u-3 polyunsaturated fatty acids 1000 mg derived
from fish oil.
Theretinalcarotenoids lutein, zeaxanthin, andmeso-zeaxanthin
accumulate in themacula,where theyare collectively referred to as
macular pigment [30]. Lutein and zeaxanthin are of dietary origin,
whereasmeso-zeaxanthin is not normally found in a conventional
diet and is thought to be generated at the retina after lutein isom-
erization [31]. In brief, macular pigment is a short-wavelength
(blue) light filter and a powerful antioxidant, and it is therefore
believed to protect against AMD. Although the concept that
macular pigment protects against AMD remains a hypothesis, the
rationale in support of this view is biologically plausible and is
supported by the findings of in vitro and animal studies in which
lutein, zeaxanthin, and meso-zeaxanthin have been shown to
protect photoreceptors against oxidative injury [32].
Currently, eye care specialists (e.g., ophthalmologists and
optometrists) find themselves in a difficult position when
attempting to make sound and evidence-based recommenda-
tions to patients at risk for visual loss from AMD. The AREDS
mixture remains the only formulation that has been shown to be
of benefit in AMD in the context of awell-designed RCT involving
a large number of patients (n ¼ 4531). However, the AREDS
formulation contained b-carotene (discussed earlier), and the
amount of zinc in the AREDS formulation exceeded the EU upper
safety limits [33]. However, it is difficult to ignore the basic
implication of AREDS, namely that antioxidants are beneficial for
patients with AMD. Such an interpretation has encouraged the
nutraceutical industry to promote the use of antioxidant
supplements that do not include b-carotene, are EU compliant,
and contain the macular carotenoids. In 2004, the Lutein Anti-
oxidant Supplementation Trial (LAST) was undertaken to inves-
tigate whether nutritional supplementation with lutein alone or
lutein plus antioxidants, vitamins, and minerals improved or
stabilized visual function in 90 patients with advanced atrophic
AMD [34]. This study reported that visual function improvedwith
lutein supplementation alone orwith luteinplus a combination of
antioxidants, vitamins, and minerals compared with a control.
One may understand why an eye care specialist, in the
absence of convincing evidence from RCTs but in the presence of
a biologically plausible rationale and significant body of sup-
porting evidence (albeit not from RCTs), might recommend
antioxidant supplements that contain themacular carotenoids in
view of the lack of other available putative or proved measures
against AMD. The patient with intermediate or advanced AMD,
who may have already lost vision in one eye, often wishes to
actively participate in decreasing the risk against further visual
loss and is unwilling to wait for a “conclusive” evidence base.
Similarly, the “worried well” who have early signs of AMD or
who have a strong family history of AMD are unlikely to be
willing to wait for definitive RCTs applicable to them, especially
in light of the excellent safety record of carotenoids when
administered at the AREDS2 dose. Nevertheless, under these
circumstances, it is incumbent on the eye care professional to
inform patients with AMD that such supplements have not been
proved to protect against the development or progression of
AMD but have strong indications of benefit.
In conclusion, while we await the outcomes of AREDS2
and other ongoing RCTs, the potential public health benefits,
scientific plausibility, and excellent safety records of lutein,
zeaxanthin, and meso-zeaxanthin are supporting the recom-
mendation that dietary consumption and supplementation with
these compounds should be encouraged. In the absence of
definitive RCTs, we must view and assess the totality of the
scientific data and weight of evidence as currently available,
identifying and acknowledging such evidence from respected
sources and scientific institutions, to find more suitable alter-
natives to RCTs to make important public health recommenda-
tions in a timely manner.
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2. Quality of carbohydrates (as expressed by the GI) in relation to
health and well-being
Food chemists have typically categorized dietary carbohy-
drates into simple sugars and complex carbohydrates on the
basis of their degree of polymerization. This form of classification
of carbohydrates is a well-established concept in food science.
However, the effect of carbohydrate on health may be better
categorized according to their physiologic effects, notably their
ability to increase blood glucose. The blood glucose response
varies substantially among different carbohydrate-containing
foods and cannot be predicted by their gross chemical compo-
sition alone. This gave rise to the concept of the GI.
The GI was developed by Jenkins et al. [35] in 1981 as an
improvement of the carbohydrate exchange list for diabetics. It is
a numerical ranking of carbohydrate foods defined as the
incremental area under the blood glucose response curve of a 50-
g carbohydrate portion of a test food expressed as a percentage of
the response to the same amount of carbohydrate from a stan-
dard food (usually white bread or glucose) taken by the same
subject. By this definition, carbohydrate foods are rated as low
(<55), medium (55–70), and high (>70) GI foods.
A series of studies have confirmed that consuming a low GI
diet (<55) has a significant effect on decreasing hemoglobin A1c
and fructosamine, confirming that the widely used cutoff points
for GI classification (<55, 55–70, and >70) have an identifiable
clinical outcome [36]. Emerging data also suggest that the
postprandial glycemic spike and the degree of blood glucose
excursion may also be of clinical importance. Foods that show
smaller peak changes in glycemia and maximum amplitude of
the glucose excursion provide greater metabolic benefits to
human subjects (Table 1) [37].
The role of fasting blood glucose in the development of
coronary heart disease is less well recognized, mainly because of
the paucity of studies correlating fasting blood glucose to coro-
nary heart disease. Bjørnholt et al. [38] reported the results from
a 22-y prospective study on fasting blood glucose as a predictor
of cardiovascular death. Of 1990 apparently healthy non-diabetic
men (40–59 y old), 1973 with fasting blood glucose levels lower
than 6.1 mmol/L (110 mg/dL) were included in the study. After
22 y of follow-up, 483 men had died, 53% from cardiovascular
diseases. It was also found that men in the highest glucose
quartile (fasting blood glucose >4.7 mmol/L [85 mg/dL]) had
a significantly higher mortality rate from cardiovascular disease
compared with those in the lowest three quartiles (Fig. 5A–C).
Another study by the Asia Pacific Cohort Studies Collaboration
[39] collated fastingbloodglucosedata from237468participants;
during approximately1.2millionperson-years of follow-up, there
were 1661 stroke and 816 ischemic heart disease events [39].
Continuous positive associations were demonstrated between
usual fasting glucose (4.9 mmol/L) and the risks of
Table 1








Low GI 49  1 1.81  0.06 1.82  0.06
Medium GI 63  1 2.20  0.06 2.21  0.06
High GI 76  1 2.45  0.04 2.49  0.05
P <0.001 <0.001 <0.001
Whole-grain breads
Low GI 49  1 1.95  0.04 2.05  0.04
Medium GI 62  1 2.21  0.03 2.24  0.04
High GI 74  1 2.29  0.05 2.29  0.05
P <0.001 <0.001 <0.005
Breakfast cereals
Low GI 46  1 2.10  0.08 2.18  0.09
Medium GI 63  1 2.60  0.08 2.78  0.08
High GI 81  2 2.89  0.08 3.02  0.08
P <0.001 <0.001 <0.001
Cereal snack bars
Low GI 43  1 2.00  0.008 2.14  0.08
Medium GI 62  1 2.66  0.09 2.82  0.09
High GI 77  2 2.93  0.11 3.07  0.10
P <0.001 <0.001 <0.001
GI, glycemic index; MAGE, maximum amplitude of glucose excursion
Fig. 5. The relation between fasting blood glucose and (A) stroke, (B) total ischemic
heart disease, and (C) cardiovascular death. Adapted from the Asia Pacific Cohort
Studies Collaboration [39]. CI, confidence interval.
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cardiovascular disease. Each 1-mmol/L decrease in usual fasting
glucose was associated with a 21% (95% confidence interval 18–
24) lower risk of total stoke and a 23% (19–27) lower risk of total
ischemic heart disease. The associations were similar in men and
women, across age groups, and in Asian compared with Austral-
asian (Australia and New Zealand) populations. Fasting blood
glucose is an important determinant of cardiovascular disease
burden,with considerablepotential benefit of usual bloodglucose
lowering down to levels of at least 4.9 mmol/L.
For several decades the diet–chronic disease paradigm has
centered on decreasing the intake of saturated fat and choles-
terol and increasing the consumption of complex carbohydrates.
The type of carbohydrate consumed may be as or more impor-
tant than the type of fat consumed: It is here that the concept of
the GI may have a significant role to play [36]. The increased
intake of refined carbohydrates (i.e., high GI carbohydrates) in
most Western diets may have aggravated the incidence of
cardiovascular disease and diabetes.
3. Probiotics in relation to intestinal and immune functions
Humans are surrounded by a world of micro-organisms. The
immune system is a complex physiologic system, the function of
which is to protect the individual against infectious diseases that
otherwise could be caused by thosemicro-organisms. Cells of the
immune system, by virtue of antigen-specific receptors, can
recognize non-self from self and thus have the ability to react to
invading micro-organisms. Along the same self/non-self prin-
ciple, the immune system also recognizes and destroys trans-
formed cells, thus protecting against malignancies. Close
regulation of the immune system is necessary because an over-
active immune system may lead to chronic inflammatory
diseases, allergic diseases, or autoimmune diseases.
The human immune system operates at two functional levels:
innate andacquired immunity. The innate responses are activated
within hours of encountering an antigen, whereas the specific
adaptive immunity takes days or weeks to develop and act.
Phagocytes and natural killer cells produce cytokines and che-
mokines that together with complements form the innate
responses. Innate immunity, in particular the dendritic cells,
initiate and orchestrate the adaptive immune system, which
consists of B and T lymphocytes. The hallmark of acquired
immunity is antigen specificity and immunologicmemory. Under
normal physiologic conditions, the immune system protects the
individual against most pathogens. The function of the immune
system can be temporarily impaired because of intrinsic or
extrinsic factors, permanently weakened in the elderly, and is not
fully mature during infancy. Even short periods of impaired
immunity can compromise the ability to fight infections.
Albers et al. [40] identified 28 different groups of markers to
measure immunomodulation in human nutrition intervention
studies. Immunoglobulin (Ig) levels in serum and at mucosal
surfaces, systemic cytokine concentrations, number and activity
of phagocytic cells, and natural killer cells are among the
biomarkers most often studied. None of these biomarkers by
themselves are indicative for the overall immune status of an
individual. The number of CD4þ T lymphocytes in peripheral
blood is an excellent marker for the immune status of patients
infected with the human immunodeficiency virus and to
monitor immune reconstitution after therapy. For healthy
individuals with CD4 counts within the normal range, this
parameter has limited value as a biomarker for the status of
the cellular immune system. The same holds true for IgA. This
class of antibodies is especially designed to function at mucosal
surfaces of the respiratory and digestive tracts. The mean
serum IgA concentration in health adults is 2.08 g/L (inter-
quartile range 1.49–2.68) [41]. Selective IgA deficiency, defined
as a serum IgA concentration below 0.05 g/L with normal levels
of IgG and IgM, is the most common form of humoral immu-
nodeficiency, occurring in about 1:700 individuals. Patients
may have severe and prolonged gastrointestinal and respira-
tory infections, but about half of individuals with selective IgA
deficiency are healthy [42]. Against this background, it is
difficult to predict, e.g., whether a 25% increase in the
concentration of secretory IgA in the mucosal surfaces of the
upper respiratory tract really would confer better protection
against influenza virus infection. This is the reason claims such
as “strengthens the immune system” are considered vague or
even meaningless, unless they relate to a more specific claimed
health effect. There is a gap between the scientific under-
standing of the immune markers and immune system and the
regulatory requirement for measuring the specific effects on
immune health [43].
The best biomarker for the status of the immune system
would be the clinical response to infection and/or the serologic
response to vaccination.
To demonstrate that probiotics can actually decrease the risk
for gastrointestinal and respiratory infections, many clinical trials
have been conducted [44]. In most cases, the study population
consisted of participants with an increased risk of infection,
namely the (very) young and the (very) old. The frequency of
respiratory tract infections in otherwise healthy toddlers in day-
care centers and the frequency of flulike infections during the
winter season in otherwise healthyelderly have been shown to be
decreased by probiotics [45]. To demonstrate the causality of the
probiotic effect on decreasing disease risk, changes in the
components of the immune system that contribute to protection
against a rhinovirus infection have been determined [45]. For
future clinical studies, therefore, biomarkers of the immune
system should be included to demonstrate the causality of the
beneficial effect [43].
The downsideof clinical trials inwhich incidence, duration, and
severityof infectiousepisodesare recorded is that inmost cases the
causative microbiological agent is not identified. This hampers the
selection of the most appropriate biomarker of the immune
system. An alternative approach to establish a cause-and-effect
relation is to deliberately infect humans with a (mild) pathogen.
This has been done for enterotoxic E. coli, Staphylococcus aureus,
and rhinovirus [46]. Such trials are costly and difficult to set up. A
more feasible approach to measure the overall effect of a nutri-
tional intervention on the invivo function of the immune system is
tomeasure the response to vaccination [47]. The two vaccines that
would be most appropriate for this purpose are influenza and
pneumococcal vaccines. In most European countries, seasonal
influenza vaccine is administered yearly to elderly and other risk
groups. It is known that in theelderly the response tovaccination is
suboptimal (and therefore provides incomplete protection).
Pneumococcal polysaccharide conjugate vaccines are incorporated
in most childhood vaccination schedules. Pneumococcal poly-
saccharide vaccines are recommended for persons older than 65 y.
For influenza and pneumococcal antibodies, assays for quantifica-
tion have been standardized and the antibody concentrations that
serve as correlates for protection have been established [48,49].
The serologic response to vaccination measures the response
of the humoral immune system. An in vivo effector function of
the cellular immune system is the so-called delayed type
hypersensitivity reaction. As yet there is limited experience with
delayed type hypersensitivity as a biomarker for cellular immune
status in nutritional intervention studies.
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The dynamic changes in systemic antibody concentrations
after vaccination can be used for the identification of beneficial
effects (of probiotics or other food components/additives) on the
immune system. Validated antibody concentrations that serve as
correlates of protection exist for the influenza and pneumococcal
vaccinations and should be used for that purpose.
4. What is the nature of evidence supporting the impact of
deficient, adequate, and optimal intakes of micronutrients on
physiologic function?
Nutritional status and physiologic responses are intimately
linked but most often lack clearly defined, specific, and vali-
dated functional tests necessary to demonstrate this relation in
a population of generally healthy people. The absence of such
assessments hampers our ability to develop new nutrient
requirements and promulgate better dietary guidelines.
Employing a classic nutritional paradigm, inadequate intakes
of essential nutrients are defined by the development of clinical
signs of awell-characterized deficiency syndrome. Depending on
the biological half-life of the specific nutrient, the symptoms of
the deficiency will be manifest as short latency diseases within
months, e.g., rickets fromvitamin D deficiency or night blindness
from vitamin A deficiency. The acute solution to this problem is
the simple intake of the nutrient and resolution of the deficiency.
In contrast, a low intake or higher biological demands of
a nutrient over a period of years may result in declining physi-
ological function and the development of a long-latency chronic
disease. The solution to this problem is more complex and
requires the use of biomarkers and/or other measurements of
assessing the slowing or reversal of the rate of the specific
pathophysiology. How then can we define adequate or optimal
nutrient intakes to promote health or decrease the risk of
a chronic disease?
To calculate the adequate intake of a nutrient sufficient to
prevent a deficiency syndrome, different reference values have
been employed. For example, the estimated average requirement
is defined as an average daily intake for healthy individuals that
achieve an established functional or clinical endpoint of
adequacy. The estimated average requirement is intended to
reflect the median for a population, i.e., half the population
should fall below and half above this value.
Importantly, the estimated average requirements listed in
Table 2 can be markedly lower than the recommended dietary
allowance and the daily value used in nutritional labeling [50]. To
specify the adequacy of intake, biochemical parameters such as
plasma or tissue status have often been employed. However, this
approach is often difficult to accomplish in large populations and
often does not accurately reflect clinical or functional outcomes.
Thus, an estimated average requirement might better be
definedusinga staticbiomarker, suchasplasmaconcentration, and
a functional measurement. For several micronutrients, including
vitamins A and E and the minerals iron and zinc, static indicators
are not available to define an adequate (or optimal) intake (Table 3)
[51]. Furthermore, this approach is currently limited to the
assessmentof the adequacyof essential nutrients and is not readily
applicable to other dietary constituents such as phytochemicals or
fatty acids other than a-linolenic and linoleic acid.
There are few good examples of establishing optimal
requirements of vitamins or other nutrients for long-latency
chronic diseases. Efforts have been undertaken to evaluate
optimal intakes of vitamin D by evaluating the results of obser-
vational studies and randomized clinical trials. Very recently, the
Institute of Medicine (IOM) presented newdietary reference data
for calcium and vitamin D [52]. The data for vitamin D were
based primarily on the intake and 25(OH)-D serum concentra-
tion needed to maintain healthy bones. The IOM panel did not
find scientific evidence for further beneficial effect of an
adequate vitamin D intake on non-skeletal benefits (for review,
see Whiting and Calvo [51]).
5. Food components with antioxidative properties and health
benefits
Many antioxidants exist in food and might exert their anti-
oxidant effects after ingestion with a meal within a complex
pattern of further known and unknown antioxidants or as an
isolated and specified antioxidant component in a food or food
supplement. Related to their nature as antioxidants, nearly all are
claimed to decrease reactive oxygen species (ROS) and subse-
quently decrease oxidative damage and compensate oxidative
stress. A major paradigm that justifies the use of antioxidants is
that ROS exposure of cells and tissues results in oxidative
damage, impairment of function, and at least a disease state. It
has been shown in some studies that ROS are responsible for the
development of different diseases such as cancer, neurologic
diseases, coronary heart disease, and other chronic degenerative
diseases [53]. The major question with respect to antioxidants
and their “evidence of benefit” is whether the detection of an
impact of antioxidants on oxidative stress might be sufficient to
claim a beneficial effect or whether a combination of a disease-
related marker and the antioxidative effect is needed. Different
analytical methods exist to measure the antioxidative activity in
humans. Because of the distribution of different ROS in different
cellular compartments, it is necessary to combine these methods
to detect intra- and extracellular ROS. In cases of degenerative
disease, the time from oxidative damage to occurrence of
Table 2
Examples of EAR [50]
Nutrient Daily value Highest RDA Population-
weighted EAR
Vitamin A 5000 IU 900 RAE 529 RAE
Folate (mg) 400 400 314
Calcium (mg) 1000 1300 1091*
Iron (mg) 18 18 6.1
Zinc (mg) 15 11 7.5
EAR, estimated average requirement; RAE, retinol activity equivalents (mg); RDA,
recommended dietary allowance
* Based on adequate intake.
Table 3






Vitamin C near maximal
leucocyte
concentration





Vitamin B12 serum B12 status maintenance of hematologic status
Vitamin B6 plasma pyridoxal-
phosphate status
(women)
urinary xanthurenic acid after
a tryptophan load (men); plasma
homocysteine concentration
Thiamin urinary thiamine erythrocyte transketolase
Riboflavin urinary riboflavin erythrocyte glutathione reductase
Niacin urinary methyl-
nicotinamide
Vitamin A adequate hepatic
vitamin A stores
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a disease-related biomarker is too long (years) to design a real-
istic human intervention study. If there is a relation between
oxidative damage and disease development, a documented
decrease of oxidative damage would be evidence of benefit
similar to the accepted evidence for the benefit of decrease of
low-density lipoprotein cholesterol. The development of
a degenerative disease is a long process and not triggered by one
effect alone. The risk for coronary heart disease increases with
high cholesterol or triacylglycerols, obesity, increased ROS
formation, or a diet with a low concentration of antioxidants.
Dietary intakes, in particular of antioxidants, are a key deter-
minant of gene expression, in part by their involvement in
genomic stability. Long-lasting degenerative diseases, such as
cancer, coronary heart disease, chronic inflammation, and accel-
erated aging, appear to be caused in part by damaged DNA. DNA
damage can be determined by measurement of micronuclei (MN)
base lesions, strand breaks, and hypo- or hypermethylation.
There are data from basic research and intriguing evidence from
human studies to suggest that insufficient intake of vitamins A,
B6, B12, E, folate, and zinc and phytochemicals, such as some
carotenoids and flavonoids, can affect the rate of spontaneous
chromosome damage. For example, to determine the effect of
nutrient intake on DNA stability, Fenech et al. [54] measured the
percentage change of MN in lymphocytes of 190 human
volunteers and found several vitamins and minerals that were
able to significantly protect DNA from damage and/or promoted
DNA repair (Fig. 6).
Thus, changes in MN frequency might be used in interven-
tion studies to evaluate the impact of different levels of
micronutrient intake. Clinical trials have already shown that
plasma statuses of folate and vitamin B12 are inversely associ-
ated with the degree of DNA hypomethylation, chromosome
breaks, and MN formation [55,56]. The formation of MN in
dividing (binuclear) cells is a result of chromosome breakage or
malsegregation, excessive uracil incorporation into DNA, or
hypomethylation of centromeric DNA [57]. Increased frequency
of MN has also been demonstrated in smokers as a result of
strand breaks or base lesions caused by oxidative stress asso-
ciated with an inadequate intake of antioxidants [58]. Further,
a lack of sufficient magnesium or calcium, minerals required for
kinetochore or spindle assembly and DNA repair, can also
increase MN formation [59]. Because MN formation changes in
relation to micronutrient intake, this method is as a sensitive
functional indicator for the optimal intake of micronutrients
necessary for genome stability.
Thus, functional indices of immune responsiveness and DNA
damage may be useful biomarkers for defining adequate and
optimal intakes of some micronutrients. These methods are
particularly suitable for evaluating in relatively small-scale
studies and, when associated with static marker or other
surrogate endpoints, can provide valuable information on the
physiologic and metabolic mechanisms related to adequate and
optimal intakes and the risk of long-latency chronic disease.
6. How to assess the effects and health benefit of botanicals as
food components?
Much of what we know about the health effects of botanicals
and botanical preparations stems from knowledge and experi-
ence that humans have accumulated over time [60]. The prop-
erties of botanicals that were part of their natural environment
were carefully observed when applied and led to the optimiza-
tion of their use within a particular society, and this process of
observation occurred long before the arrival of clinical trials and
sophisticated analytical methods.
In Europe, medicinal law has accepted this observational
approach and provides for a simplified registration based on
traditional use for medicinal products [61]. Food law, however,
expects RCTs to demonstrate health effects [62]. Such data are not
available in most cases for botanicals and the regulatory process
risks eradicating much of the heritage of acquired knowledge.
Furthermore, addressing the beneficial effects of botanicals
and botanical components on health using RCTs presents chal-
lenges that cannot in the current state of science be solved.
 An approach to assess the efficacy of individual molecular
substances is not adapted to be applied to complex mixtures
of naturally occurring substances as present in botanicals.
For single molecules, the pharmacokinetics and pharmaco-
dynamics can easily be studied and clinical trials easily set
up; for the complex mixtures that botanicals are, it is nearly
impossible to use the same methodology [63,64].
 The demonstration of a physiologic effect in healthy people
by intervention trials is almost impossible because it
concerns an effect beneficial to the maintenance of a healthy
Fig. 6. Decrease or increase (percentage) of MN due to different dosages of vitamins [54]. bC, b-carotene; Ca, calcium; FS, folic acid; MN, micronuclei; NS, nicotinic acid; PA,
pantothenic acid; VA, vitamin A; VE, vitamin E.
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normal state (homeostasis) and to people not having
symptoms of pathologies [65]. It is therefore nearly impos-
sible to determine and assess adequate markers and to
define these with precision in healthy people.
 Effects relating to the maintenance of a health status often
become obvious over a long period (sometimes years or even
decades). It is not feasible to assess such effects through
intervention trials. Observational evidence and knowledge
acquired over time are valid elements and therefore part of
the evidence to help judge the strength, plausibility, and
consistency of a certain effect on health [66,67].
 New techniques such as metabolomics are emerging and
could perhaps solve in the distant future some problems
linked to the use of complex systems such as botanicals [68].
However, this technique is extremely expensive, needs
chemically verywell-defined extracts, and the outcomeswill
probably not be valid in the foreseeable future until suffi-
cient reference data have been built up [69].
The use of the vast body of empirical and traditional knowl-
edge available for many botanicals and their preparations is
therefore essential for the appreciation of their beneficial effects.
This volume of traditional and empirical knowledge is gradually
being confirmed by fundamental and applied research and
reported in the scientific literature because of the current
possibilities of phytochemical research and pharmaco-toxico-
clinical study of the components of these plants.
The European nutrition and health claims legislation has
formalized the approval of health claims on foods, and the
traditional use of many botanicals now falls within this frame-
work. They all risk being rejected because of the reliance on RCTs,
which are not available for this group of products. Although for
decades botanicals have been accepted on the basis of experi-
ence, a new approach needs to be developed to enable a judg-
ment on the validity of traditional use for botanicals. It is
therefore proposed that, for the purpose of claims assessment,
documentation needs to be provided to demonstrate traditional
use of a botanical or botanical preparation for a certain health
effect and all possible sources of information should be consid-
ered. The more evidence there is from these various sources, the
stronger is the support for an acceptable tradition of use.
 Health effects of botanicals and botanical preparations have
been recorded over time in historic and ethnobotanic
records, botanical reference textbooks, monographs, etc. The
more extensive these records describe the observed effect,
the stronger the support for a traditional effect.
 It must be clear that the botanical preparation for which
traditional information is used must be in line with the
traditional form (e.g., infusions, aqueous or hydroalcoholic
extracts, or their dried form). The more a product deviates
from its traditionally used form and conditions of use, the
less certainty there is about the validity of the traditionally
observed physiologic effect.
 There are multiple recent reviews or compilations of tradi-
tional health effects in variousmonographs (WHO, European
Scientific Cooperation on Phytotherapy, The Committee on
Herbal Medicinal Products, Pharmacopeia, Kommission E,
leading experts in this field, etc.) that are generally recog-
nized as authoritative and can be used to help substantiate
the effect [70].
 Further evidence can be given by more recent experimental
and applied scientific data that confirm the effect or are
indicative of the underlying biological mechanism.
Pharmacologic data from chemical classes to which the
known components of the botanical or the preparation
belong may also support the plausibility of the traditional
effect [71,72].
Once this information is collected, a good overview on the
traditional and scientific knowledge of a botanical or botanical
preparation will be available and allow an assessment of the
validity and strength of the traditional claim.
III. Role of various types of scientific data: clinical trials,
meta-analysis, and observational and traditional evidence
One particular field of discussion is the value of the various
sources of scientific data in support of a diet–health relation. This
includes the advantages and limitations of sources including RCTs,
meta-analysis, observational evidence, and traditional use in the
process of assessing the evidence for diet–health relations. This
section addresses these aspects of the claims assessment process.
Consensus statement
There is a need to propose criteria for the identification of
pertinent data and identify methodologies available to address the
totality of this evidence according to the strength of the various
study designs and results (as is applied to the assessment for diet–
health relations as the basis for public health recommendations).
There is a need to consider the “inverse precautionary principle”:
if the evidence is not absolutely conclusive but substantially indic-
ative of the effect, then take a management decision to allow the
claimed effect for the benefit of the consumer. An assessment of the
evidence should contain the necessary information to make such
management decisions possible.
The evidence needed should be proportionate to the strength
of the claim.
1. Are RCTs capable of addressing the complex interactions of
dietary interventions and of isolating the effects of individual food
components within the food matrix?
In section I, it was concluded that experience suggests that
current assessments depend too much on evidence from RCTs,
which was not PASSCLAIM’s intention. Furthermore, RCTs,
whether “explanatory” or “pragmatic,” are not always possible or
appropriate.
The presence or absence of positive RCT data should not
therefore be a gate-keeper criterion in the evaluation of nutrient
or food claims for several reasons.
 For applications involving new indications for a recognized
essential nutrient, an adequate RCT would not be ethically
permissible because the control group would have to be
placed on an intake low enough to result in the untoward
outcomes that an adequate intake would have prevented.
Prospective cohort studies, case–control studies, observa-
tional studies of high quality, crossover studies, and exper-
imental data can contribute to the totality of evidence in
cases when a RCT is impossible or unethical.
 Even when a RCT would be ethically permissible, the capa-
bility of RCT designs for foods or nutrients is markedly
limited for the control of critical effect modifiers such as
synergies with a multitude of other nutrients and the
influence of nutrigenomic relations.
 Because of the ubiquity of nutrients, for most nutritional inter-
ventions tested in a RCT, a true placebo or control group is often
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not possible because no dietary pattern can feasibly exclude
exposure to the test nutrient before and/or during the trial.
 Where validated intermediary biomarkers are not available,
the duration of a RCT to test the ability of a nutritional
intervention for the primary prevention of a chronic disease
may require a decade or more and thousands of subjects.
Thus, if required as a necessary criterion for evidence of
a health benefit, RCTs often do not present a feasible
research approach. Their being required impedes innova-
tions and applications by the food and nutritional industries.
 Society does not need the same level of certainty concerning
the effect of a low-risk nutrient or food as it does for
a potentially higher-risk (and much more expensive) drug.
For example, if the input/exposure concerned is lower than
the amount listed as safe by responsible authorities (e.g.,
lutein) and if observational studies indicate the likelihood of
a favorable effect, such a claim could be accepted because
the harm of not accepting (i.e., possible benefits forgone)
would outweigh the harm of approval (which would appear
to be negligible even if the effect is actually null). Each case
needs to be evaluated individually and on its ownmerits, but
the absence of RCT evidence in such cases should not
preclude evaluation of a submission. In addition, to require
for a low-risk nutrient the assurance appropriately neces-
sary for a new drug is likely to stifle product innovation.
What has been termed the inverse precautionary principle
may be helpful in this context. If the evidence is not abso-
lutely conclusive but substantially indicative of the effect,
then amanagement decision to allow the claimed effect may
be taken for the benefit of the consumer.
Although it is certainly true that the RCT is the only trial
design that supports strong causal inference, this statement is
correct only if the RCT meets several criteria.
 Generalizability to the target population.
 Minimal losses of participants during the trial.
 The doses/exposures of the several contrast groups are
adequate to elicit thehypothesized contrastof effects (Figs. 7, 8).
 Intakes of other nutrients or foods, on which the tested
nutrient is dependent, must be optimized.
Lacking any of these, an RCT, whether positive or null, will
often provide less certainty than well-constructed, prospective
observational studies.
In addition, null RCT data should not be construed as indi-
cating that a given food component does not produce a claimed
effect unless it can be shown that the dose/exposure was
adequate and that the baseline status was low enough to have
resulted in the untoward effects that a higher dose would
presumably have prevented (Figs. 7, 8).
In case RCT data (or the possibility of developing such) are
lacking, alternative lines of evidence should be considered.
 If a proposed claim is supported by two or more well-
designed prospective cohort studies, each with an appro-
priate sample size, if they come from different populations, if
all find a similar effect, and if there is a plausible biological
basis for the postulated action, such a claim could be
approvable.
 Metabolic and nutrigenomic investigations can also provide
valuable information regarding mechanisms of action rele-
vant to health outcomes and thus contribute substantially to
the biological plausibility of the relation.
 In general, the strength, consistency, and biological plausi-
bility of the evidence should be reflected in the wording of
the claim, e.g., claims based on strong evidence or moderate
levels of evidence.
2. What are the strengths and limitations of meta-analyses and
systematic reviews in nutritional research?
Systematic reviews and meta-analyses are valuable tools
summarizing the scientific data available and pointing toward
findings that could be regarded as generally accepted. However,
Fig. 7. Typical sigmoid response curve showing the response across different
intakes of a given nutrient. Depicted are the expected responses from equal
increases in nutrient intake, starting from a low basal intake and moving to
progressively higher levels. Intake increments A, B, and C produce responses a, b,
and c, respectively. Only intakes in the B region produce large-enough responses to
test the hypothesis that the nutrient concerned elicits the response in question.
( 2010 by Robert P. Heaney, M.D. All rights reserved. Used with permission).
Fig. 8. Three typical sigmoid response curves showing differences in response to
any given intake exhibited by three organ systems within the same individual. A
given intake increment (open arrow) intersects the three responses in different
regions of their respective curves. Thus, the increment shown, starting from
a certain basal intake/status, will produce a measurable response in system B, but
not in system A or C. For system A, the response occurred at a lower intake, and
little more could be expected from further increases. For system C, still higher
intakes were needed to produce a perceptible response. ( 2010 by Robert P.
Heaney, M.D. All rights reserved. Used with permission).
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they need to employ the relevant biological criteria (in addition
to the usual methodologic criteria) for the inclusion of studies for
estimation of aggregate effects. Reviews and meta-analyses
whose outcomes are null and that have included studies that
failed to meet the criteria listed earlier should not be accepted as
evidence against a claim.
IV. The future of nutritional research
This session addresses whether claims relating to the mainte-
nance of health would need to be assessed in a different way than
claims that relate to the decrease of the development of a disease
and what is the role of generally accepted scientific evidence in this
respect.
Consensus statement
There is a need to address alternative methodologies for the
assessment of health effects, where appropriate, targeted to indi-
vidual physiologic mechanisms.
Over the past century, the research of the relation of diet to
health has seen some major transitions, mostly following
biochemical and biomedical paths. On the one hand, molecular
mechanisms were discovered (energy metabolism, vitamin
biochemistry); on the other hand, observations were made on
long-term health effects, mostly from a negative (unhealthy,
disease) viewpoint. The combination of these two tracks has led
to the “paradigm” that optimal nutrition prevents disease and
thus disease-related mechanisms and related biomarkers should
be used to quantify the effect of a dietary intervention. This mode
of working was carried to perfection with the recent boost in
biological and biomedical sciences, but in the end essentially
demonstrated that this only partly works in nutrition research.
Nutrition is not only about preventing disease progression but
also about maintaining optimal health and physiologic functions.
Nonetheless, this created major difficulties because essentially
no “biomarkers of health” were available, and the absence of
elevated disease/damage biomarkers was correctly not regarded
as indicative for nutritional effects [73].
It is now realized that there needs to be a re-evaluation of the
core role of nutrition in relation to physiology. Apart from
providing energy, the essential role is to facilitate optimal func-
tioning of all physiologic processes in the context of an
ever-changing environment. Physiology is not static but contin-
uously adapting to environmental and chronobiological changes:
energy pulses, physical exercise, increased blood pressure,
oxidative stress, mental stress, infections, prolonged caloric
restriction, changing diurnal rhythms, etc. As an example,
a simple glucose diet induces changes not only in glucose and
insulin but also in cholesterol, triacylglycerols, oxidative stress,
blood pressure, and adiponectin, i.e., all rapidly changing “risk
factors” of themetabolic syndrome [74]. Themolecular processes
underpinning these processes are quantifiable and new
“biomarkers” emerge from assays that apply perturbation of
homeostasis as a measurement of health [21,75]. With the
inclusion of new analytical technologies in these perturbation
assays, a wealth of information on the molecular physiology of
adaptation emerges, as in the case of the oral glucose tolerance
test [76–78].
The application of this concept in various areas of functional
adaptation processes will produce new biomarkers of health.
Immune function is a typical example, where “homeostatic”
values of molecular reporters (cytokines, bioactive lipids) or
functional parameters (cell counts, cellular assays) are non-
informative and in fact should not change in a healthy
person on a diet that “increases resistance.” However, the
recovery time after infection is a clear measurement of
immune-related resistance and is used in dietary intervention
studies [79].
Perhaps the final step is to skip theword biomarker, which has
become a paradigm in itself. We are now approaching the stage
in biological research where we describe, understand, and
quantify the molecular physiologic processes instead of a single
parameter in a single point in time that is supposed to capture
biological complexity. Nutrition is about health, and once we
capture the relevant processes involved in maintaining optimal
health, i.e., that continuously adapt under a variety of pertur-
bations, we refocus on the real role of nutrition. In contrast to
100 y ago, we can do this with the help of rapidly increasing
biological knowledge and a wide array of newly emerging
technologies.
Conclusion
All types and sources of data need to be considered in the
weighing of the totality of the evidence, and the best and most
logical resource to assess the evidence available in support of the
biological plausibility and probability of the beneficial role of
a nutrient or food component is by gathering the experts in the field
and reaching conclusions in the form of a scientific consensus. This
assures that the totality of the evidence is considered and that
conclusions are reached in the best knowledge of the current state of
scientific research.
The EU PASSCLAIM project supports this approach but provides
no indications on how the overall totality of the evidence should be
weighed and interpreted. Several different scientific bodies have
considered systems for assessing and grading the evidence to
establish the strength, consistency, and biological plausibility of
a diet–health relation and enable regulators to make decisions on
public health recommendations and claims approvals in the best
knowledge of the facts. All the various sources of available scientific
data should be considered, including observational and mechanistic
data, practice of health care professionals, and, in particular for
botanicals, evidence of traditional use. Where the evidence is not
conclusive, there is a good reason to apply the inverse precautionary
principle, meaning that if the evidence is not conclusive but
substantially indicative of the effect, then a management decision to
allow the claimed effect may be taken for the benefit of the
consumer.
The outcome of this consensus conference highlights that the
assessment of the relation between intake of a food or food
constituent and a beneficial health effect is a complex process. It can
be performed based largely on the outcome of RCTs, and it is not
disputed that well-conducted RCTs offer the strongest support for
cause-and-benefit relations. However, this is the case only if RCTs
meet several essential criteria. Furthermore, RCTs are not always
possible or available and are seldom capable of addressing the
broad field of interactions of the human physiology. RCTs are
a difficult tool for nutritional studies, unless the food component of
interest has much in common with a pharmaceutical compound.
Therefore, the presence or absence of positive RCT data should not
be a gate-keeper criterion in the evaluation of a claims assessment
process.
Research in the field of nutrition has entered a new stage, where
it deserves its own nutritional methodologies that are distinct and
more diverse than evidence- based medicine. It requires redefining
health in terms of an individual’s potential to adapt to internal and
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external stimuli rather than using the pharmaceutical paradigm.
New ways of addressing nutritional and functional effects of foods
and food components are being developed and offer opportunities
for future research. Any claims assessment system that is not able to
accommodate the wide spectrum of health effects should be adap-
ted to reflect the science available. It should be capable of stimu-
lating these developments toward new research and the
development of innovative products and useful information to the
benefit of the consumer, including but not limited to public health
messages.
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Appendix. Various systems proposed for grading of
evidence for different types of claims
Function claims [14]
This methodology was established by the Netherlands Ministry of Health and
proposed in December 2004 as a systematic approach for a generic list of
health claims under the NHCR (Article 13).
Convincing level of evidence would constitute support from
Category 5 evidence: text handbooks, monographs, judgment by government-
related organizations, scientific groups, or expert organizations (e.g., WHO,
SCF, etc.), critical reviews by independent experts
Category 4 evidence: meta-analysis, peer-reviewed publications, critical reviews
by experts
Probable level of evidence would constitute support from
Category 3 evidence: 1 publication of meta-analysis on peer-reviewed articles
demonstrating that “positive outweighs the negative,” 1 large human study
with supportive epidemiologic and/or laboratory data, multiple small human
studies with good designs and consistent results
Insufficient level of evidence would constitute support only from
Category 2 evidence: epidemiologic data, even with consistent results (unless
supported by biological plausibility and consistent laboratory data), 1 small
human study with supportive laboratory data, 1 large human study with
contradictory epidemiologic and/or laboratory data, multiple small human
studies showing consistent results but with flawed design or with good
designs but showing contradictory results
Category 1 evidence: in vitro or animal (laboratory) data only, 1 small human
study or several small uncontrolled human studies, epidemiologic data with
contradictory results
Decrease of disease risk claims (World Cancer Research Fund as modified by the
WHO [12])
This methodology was used to grade the strength of evidence linking dietary and
lifestyle factors to the risk of developing diseases including obesity, type 2
diabetes, cardiovascular disease, cancer, dental diseases, and osteoporosis.
Convincing level of evidence would consist of evidence based on epidemiologic
studies showing consistent associations between exposure and disease, with
little or no evidence to the contrary. The available evidence is based on
a substantial number of studies including prospective observational studies
and, where relevant, randomized controlled trials of sufficient size, duration,
and quality showing consistent effects. The association should be biologically
plausible.
Probable level of evidence: evidence based on epidemiologic studies showing
fairly consistent associations between exposure and disease, but where there
are perceived shortcomings in the available evidence or some evidence to the
contrary, which precludes a more definite judgment
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Shortcomings in the evidence may be any of the following: insufficient duration
of trials (or studies); insufficient trials (or studies) available; inadequate
sample sizes; incomplete follow-up. Laboratory evidence is usually
supportive. The association should be biologically plausible.
Possible level of evidence: evidence based mainly on findings from case–control
and cross-sectional studies; insufficient randomized controlled trials,
observational studies, or non-randomized controlled trials are available;
evidence based on non-epidemiologic studies, such as clinical and laboratory
investigations, is supportive; more trials are required to support the tentative
associations, which should also be biologically plausible
Insufficient level of evidence: evidence based on findings of a few studies that are
suggestive but insufficient to establish an association between exposure and
disease; limited or no evidence is available from randomized controlled trials;
more well-designed research is required to support the tentative associations
Medicinal products*
This methodology for the grading of evidence was developed by the EMEA as
a guide for national authorities to grade the level of evidence of published
literature submitted in well-established use applications and to assure that
the level of evidence and the grading of recommendations correspond to the
nature of the disease that is to be treated.
It does not apply to new medicinal products that need specific preclinical tests
and clinical trials and to traditional herbal medicinal products that need only
demonstration of traditional use if the effect is plausible on the basis of
traditional use.
Grade A evidence: requires 1 randomized controlled trial as part of the body of
literature of overall good design and consistency addressing the specific
recommendations; it would be expected to come from
Evidence obtained from meta-analysis of randomized controlled trials (category
1a evidence)
Evidence obtained from 1 randomized controlled trial (category 1b evidence)
Grade B evidence: requires availability of well-conducted clinical studies but no
randomized clinical trials on the topic of recommendation. It would be
expected to come from
Evidence obtained from 1 well-designed controlled study without
randomization (category 2a evidence)
Evidence obtained from 1 other type of well-designed quasi-experimental
study (category 2b evidence)
Evidence obtained from well-designed non-experimental descriptive studies,
such as comparative studies, correlation studies, and case–control studies
(category 3 evidence)
Grade C evidence: requires evidence from expert committee reports or opinions
and/or clinical experience of respected authorities; indicates absence of
directly applicable studies of good quality; it would be expected to come from
Evidence obtained from expert committee reports or opinions and/or clinical
experience of respected authorities (category 4 evidence)
In addition, the EMEA distinguished different levels of claims for medicinal
effects (herbal drugs) [15]:
Major claims (minimumrequirements for high level of evidence: level Ia, Ib), e.g., for
the treatment, cure,management,orpreventionofanyseriousdiseaseordisorder
Medium claims (minimum requirements for medium level of evidence: level IIa,
IIb, III), e.g., decrease of the risk of a disease/disorder; decrease in the
frequency of a discrete event; aids/assists in the management of a named
symptom/disease/disorder; relief of symptoms of a named disease or disorder
Minor claims (minimum requirements for general level of evidence: level IV),
e.g., relief or management of symptoms of a minor, self-limiting disease/
disorder that does not require medical intervention for diagnosis or
monitoring; description of a pharmacologic action related to management of
symptoms of a self-limiting disease/disorder that does not require medical
intervention for diagnosis or monitoring
EMEA, European Medicines Agency; NHCR, Nutrition and Health Claims Regu-
lation; SCF, Scientific Committee on Food; WHO, World Health Organization
* EMEA Working Party on Herbal Medicinal Products. Updated draft points to
consider on the evidence of safety and efficacy required for well-established
herbal medicinal products in bibliographic applications. EMEA/HMPWP/23/99.
London, October 25, 1999.
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